Table 2.
Biomarker Data
| |
Study visit |
|||||||
|---|---|---|---|---|---|---|---|---|
| |
Baseline |
Week 84 |
Week 144 |
|||||
| 10-Year Framingham CHD risk score | n | Median (Q1–Q3) | n | Median (Q1–Q3) | p-valuea | n | Median (Q1–Q3) | p-valuea |
| hsCRP (mg/liter) | ||||||||
| ATV and ATV/r arms combined | ||||||||
| <6% | 285 | 1.6 (0.6–3.4) | 280 | 1.6 (0.6–2.9) | 0.677 | 249 | 1.4 (0.6–3.4) | 0.535 |
| ≥6% | 61 | 1.9 (0.9–2.8) | 60 | 1.7 (0.8–4.9) | 0.589 | 50 | 2.0 (1.2–5.0) | 0.102 |
| All | 346 | 1.6 (0.7–3.3) | 340 | 1.6 (0.6–3.3) | 0.901 | 299 | 1.5 (0.6–3.7) | 0.949 |
| ATV arm alone | ||||||||
| <6% | 147 | 1.5 (0.6–3.5) | 144 | 1.6 (0.7–3.4) | 0.460 | 128 | 1.2 (0.6–2.6) | 0.636 |
| ≥6% | 31 | 1.8 (0.7–3.6) | 30 | 1.5 (0.8–3.5) | 0.480 | 25 | 1.9 (0.8–5.3) | 0.076 |
| All | 178 | 1.6 (0.6–3.5) | 174 | 1.6 (0.7–3.5) | 0.620 | 153 | 1.3 (0.6–3.4) | 0.825 |
| ATV/r arm alone | ||||||||
| <6% | 138 | 1.6 (0.6–3.4) | 136 | 1.4 (0.5–2.7) | 0.164 | 121 | 1.5 (0.6–3.7) | 0.669 |
| ≥6% | 30 | 2.0 (1.0–2.7) | 30 | 2.1 (0.7–6.5) | 0.176 | 25 | 2.0 (1.3–4.4) | 0.607 |
| All | 168 | 1.6 (0.7–3.1) | 166 | 1.6 (0.6–3.1) | 0.502 | 146 | 1.5 (0.7–4.0) | 0.866 |
| IL-6 (pg/ml) | ||||||||
| ATV and ATV/r arms combined | ||||||||
| <6% | 287 | 1.6 (1.0–2.5) | 287 | 1.2 (0.8–2.0) | <0.001 | 249 | 1.4 (0.9–2.3) | 0.267 |
| ≥6% | 61 | 2.0 (1.3–2.6) | 61 | 1.8 (1.2–2.7) | 0.522 | 50 | 2.2 (1.5–3.5) | 0.099 |
| All | 348 | 1.6 (1.0–2.5) | 348 | 1.3 (0.8–2.1) | <0.001 | 299 | 1.5 (1.0–2.6) | 0.846 |
| ATV arm alone | ||||||||
| <6% | 147 | 1.6 (1.0–2.6) | 147 | 1.2 (0.8–2.2) | 0.003 | 128 | 1.4 (0.9–2.4) | 0.442 |
| ≥6% | 31 | 1.9 (1.1–3.1) | 31 | 1.5 (1.1–2.1) | 0.422 | 25 | 1.9 (1.4–3.4) | 0.638 |
| All | 178 | 1.6 (1.0–2.6) | 178 | 1.3 (0.8–2.2) | 0.003 | 153 | 1.5 (1.0–2.4) | 0.596 |
| ATV/r arm alone | ||||||||
| <6% | 140 | 1.5 (1.0–2.4) | 140 | 1.2 (0.8–2.0) | <0.001 | 121 | 1.3 (0.8–2.3) | 0.420 |
| ≥6% | 30 | 2.1 (1.4–2.6) | 30 | 2.2 (1.2–2.9) | 0.897 | 25 | 2.4 (1.8–4.2) | 0.065 |
| All | 170 | 1.6 (1.1–2.5) | 170 | 1.3 (0.9–2.1) | 0.002 | 146 | 1.5 (1.0–2.8) | 0.809 |
| Lp-PLA2 (nmol/min/ml) | ||||||||
| ATV and ATV/r arms combined | ||||||||
| <6% | 284 | 197 (162–238) | 287 | 189 (150–217) | <0.001 | 249 | 168 (138–198) | <0.001 |
| ≥6% | 60 | 238 (202–278) | 61 | 210 (176–238) | <0.001 | 50 | 175 (147–213) | <0.001 |
| All | 344 | 203 (166–250) | 348 | 191 (153–220) | <0.001 | 299 | 171 (138–199) | <0.001 |
| ATV arm alone | ||||||||
| <6% | 146 | 193 (159–224) | 147 | 180 (147–211) | <0.001 | 128 | 165 (138–197) | <0.001 |
| ≥6% | 30 | 238 (206–285) | 31 | 211 (177–246) | 0.010 | 25 | 172 (149–199) | <0.001 |
| All | 176 | 197 (160–237) | 178 | 185 (154–217) | <0.001 | 153 | 165 (139–198) | <0.001 |
| ATV/r arm alone | ||||||||
| <6% | 138 | 208 (170–253) | 140 | 195 (151–221) | <0.001 | 121 | 169 (137–199) | <0.001 |
| ≥6% | 30 | 237 (198–277) | 30 | 202 (169–238) | <0.001 | 25 | 175 (147–216) | <0.001 |
| All | 168 | 212 (174–255) | 170 | 195 (152–225) | <0.001 | 146 | 172 (137–206) | <0.001 |
a
p-values from Wilcoxon signed-rank test comparing baseline and postbaseline.
CHD, coronary heart disease; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; Lp-PLA2, lipoprotein-associated phospholipase A2; Q1–Q3, first quartile through third quartile; ATV/r, atazanavir/ritonavir.